Cite
Novartis presents new five-year data on disability outcomes and safety of Kesimpta (ofatumumab) in people living with relapsing multiple sclerosis
MLA
“Novartis Presents New Five-Year Data on Disability Outcomes and Safety of Kesimpta (Ofatumumab) in People Living with Relapsing Multiple Sclerosis.” PR Newswire, 20 Apr. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.746238538&authtype=sso&custid=ns315887.
APA
Novartis presents new five-year data on disability outcomes and safety of Kesimpta (ofatumumab) in people living with relapsing multiple sclerosis. (2023, April 20). PR Newswire.
Chicago
PR Newswire. 2023. “Novartis Presents New Five-Year Data on Disability Outcomes and Safety of Kesimpta (Ofatumumab) in People Living with Relapsing Multiple Sclerosis,” April 20. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.746238538&authtype=sso&custid=ns315887.